- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Teva Launches First Generic to Blockbuster Cancer Med
This is the first generic available for Revlimid in the United States.
Teva Pharmaceuticals launched lenalidomide, the first generic version of Celgene Corp.’s blockbuster cancer treatment Revlimid (lenalidomide capsules).
Revlimid, which treats multiple myeloma in combination with dexamethasone (Decadron, other brand names), myelodysplastic syndromes (specifically patients with a deletion of some part of chromosome 5), and mantle cell lymphoma, had annual sales of $2.3 billion as of 2021, according to IQVIA, Teva said in a news release.
Lenalidomide capsules will be available immediately in the United States in 5 mg, 10 mg, 15, mg, and 25 mg strengths. The drug also treats certain myelodysplastic syndromes.
“The launch of our first generic version of Revlimid in the United States provides patients with another important treatment option for these extremely challenging conditions, demonstrating Teva’s commitment to making complex generic drugs available to the patients who need them,” said Christine Baeder, senior vice president and chief operating officer of U.S. generics at Teva USA.
Lenalidomide adds to Teva’s generic portfolio of oncology treatments, which accounts for 73% of the essential medicines in this category, according to the company.
Additionally, Sandoz recently announced that it has launched a generic of lenalidomide in 19 countries across Europe.
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
